Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrutinib + CD20 Ab +/- Venetoclax in Untreated Mantle Cell Lymphoma
NCT04802590Phase 2Active, not recruiting
- Sponsor
- LYSARC
- Start
- Jan 2022
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of venetoclax in mantle cell lymphoma (MCL), sponsored by LYSARC. Started Jan 2022; status: active, not recruiting.
02
Drugs
venetoclax
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT04802590.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04802590.